Search Result

Results for "

γ-Secretase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	γ-secretase (97) Akt (1) Amyloid-β (30) Apoptosis (13) ATM/ATR (1) Autophagy (1) Beta-secretase (5) Biochemical Assay Reagents (1) Cholinesterase (ChE) (2) Drug Derivative (1) Drug Metabolite (2) Ferroptosis (1) Fungal (1) HIF/HIF Prolyl-Hydroxylase (1) Isotope-Labeled Compounds (1) Liposome (1) mTOR (1) NF-κB (1) Notch (16) Organoid (2) Proteasome (2) PTEN (1) Reference Standards (8) Src (1) VEGFR (1)
By Research Areas:	Cancer (30) Infection (1) Inflammation/Immunology (4) Metabolic Disease (6) Neurological Disease (84)
Oligonucleotides:	Cationic Lipids (1)

114

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Oligonucleotides

GMP Molecules

Targets Recommended: γ-secretase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13027

DAPT Maximum Cited Publications 158 Publications Verification GSI-IX	Organoid γ-secretase Amyloid-β Autophagy Notch Apoptosis	Neurological Disease Inflammation/Immunology Cancer
DAPT (GSI-IX) is a potent and orally active *γ-secretase* inhibitor with IC₅₀s of 115 nM and 200 nM for total amyloid-β (Aβ) and Aβ₄₂, respectively. DAPT inhibits the activation of Notch 1 signaling and induces cell differentiation. DAPT also induces autophagy and apoptosis. DAPT has neuroprotection activity and has the potential for autoimmune and lymphoproliferative diseases, degenerative disease and cancers treatment .

HY-14176

Compound E 15+ Cited Publications γ-Secretase-IN-1	γ-secretase	Cancer
Compound E is a *γ-secretase* inhibitor. Compound E blocks β-amyloid(40), β-amyloid(42), and Notch γ-secretase cleavage with IC₅₀s of 0.24, 0.37, 0.32 nM, respectively.

HY-13526

YO-01027 5+ Cited Publications Dibenzazepine; DBZ	Notch γ-secretase	Cancer
YO-01027 (Dibenzazepine;DBZ) is a potent *γ-secretase* inhibitor with IC₅₀ values of 2.92 and 2.64 nM for Notch and APPL cleavage, respectively.

HY-50752

LY-411575 25+ Cited Publications	Organoid γ-secretase Notch Apoptosis	Neurological Disease
LY-411575 is a potent *γ-secretase* inhibitor with IC₅₀ of 0.078 nM/0.082 nM (membrane/cell-based), and also inhibits Notch S3 cleavage with an IC₅₀ of 0.39 nM.

HY-15185

Nirogacestat 10+ Cited Publications PF-3084014	γ-secretase Apoptosis	Cancer
Nirogacestat (PF-3084014) is a reversible, orally bioavailable, noncompetitive, and selective *γ-secretase* inhibitor with an IC₅₀ of 6.2 nM. Inhibition of Notch signaling by Nirogacestat while minimizing gastrointestinal toxicity presents a promising approach for research of Notch receptor-dependent cancers .

HY-10974

MK-0752 10+ Cited Publications	γ-secretase	Neurological Disease Cancer
MK-0752 is a potent, orally active and specific *γ-secretase* inhibitor, showing dose-dependent reduction of Aβ40 with an IC₅₀ of 5 nM in human SH-SY5Y cells. MK-0752 crosses the blood-brain barrier. MK-0752 reduces newly generated CNS Aβ in vivo .

HY-18236

MDL-28170 15+ Cited Publications Calpain Inhibitor III	Proteasome	Neurological Disease Inflammation/Immunology
MDL-28170 (Calpain Inhibitor III) is a potent, selective and membrane-permeable cysteine protease inhibitor of calpain that rapidly penetrates the blood-brain barrier following systemic administration . MDL-28170 also block γ-secretase .

HY-50845

Avagacestat 2 Publications Verification BMS-708163	γ-secretase Notch	Cancer
Avagacestat (BMS-708163) is a potent inhibitor of *γ-secretase, with IC₅₀s of 0.27 nM and 0.30 nM for Aβ42 and Aβ40 inhibition; Avagacestat (BMS-708163) also inhibits NICD (Notch IntraCellular Domain) with IC₅₀* of 0.84 nM and shows weak inhibition of CYP2C19, with IC₅₀ of 20 μM. Avagacestat can be used for Alzheimer disease research.

HY-12449

Crenigacestat 5+ Cited Publications LY3039478	Notch γ-secretase	Cancer
Crenigacestat (LY3039478) is an orally active Notch and *γ-secretase* inhibitor, with an IC₅₀ of 1 nM in most of the tumor cell lines tested .

HY-10009

Semagacestat 10+ Cited Publications LY450139	γ-secretase Amyloid-β Notch	Neurological Disease
Semagacestat is a *γ-secretase* inhibitor, inhibits β-amyloid (Aβ42), Aβ38 and Aβ40 with IC₅₀s of 10.9, 12 and 12.1 nM, respectively; also inhibits Notch signaling with IC₅₀ of 14.1 nM. Semagacestat can be used for the research of alzheimer's disease .

HY-19369

L-685458 5+ Cited Publications L-685,458	γ-secretase Apoptosis	Neurological Disease Cancer
L-685458 is a potent transition state analog (TSA) *γ-secretase* inhibitor (GSI). L-685458 inhibits amyloid β-protein precursor γ-secretase activity with IC₅₀ of 17 nM, shows greater than 50-100-fold selectivity over other aspartyl proteases tested. L685458 inhibits γ-secretase-mediated cleavage of APP-C99 and Notch-100 with IC₅₀s of 301.3 nM and 351.3 nM, respectively. L-685458 can be used for the research of alzheimer’s disease (AD) and cancers .

HY-171306

MK16	Liposome	Others
MK16 is a lipid material that can be used to construct blood-brain barrier penetrable lipid nanoparticles for mRNA delivery. MK16 facilitates blood-brain barrier crossing via γ-secretase-mediated and caveolae-mediated transcytosis. MK16 can be used for drug delivery research .

HY-12465

Z-Ile-Leu-aldehyde 2 Publications Verification Z-IL-CHO; GSI-XII; γ-Secretase inhibitor XII	Notch γ-secretase Apoptosis	Cancer
Z-Ile-Leu-aldehyde (Z-IL-CHO) is a potent and competitive peptide aldehyde inhibitor of *γ-secretase* and notch .

HY-14399

Itanapraced 1 Publications Verification CHF5074; CSP-1103	γ-secretase Apoptosis	Neurological Disease
Itanapraced (CHF5074) is an orally active *γ-secretase* modulator and a non-steroidal anti-inflammatory derivative. Itanapraced reduces Aβ42 and Aβ40 secretion with IC₅₀ values of 3.6 and 18.4 μM, respectively. Itanapraced inhibits cell apoptosis of hippocampal neurons induced by oxygen and glucose deprivation (OGD). Itanapraced can be used for the research of Alzheimer's disease .

HY-15185B

Nirogacestat dihydrobromide 10+ Cited Publications PF-3084014 dihydrobromide; PF-03084014 dihydrobromide	γ-secretase Apoptosis	Cancer
Nirogacestat dihydrobromide (PF-3084014 dihydrobromide) is a reversible, orally bioavailable, noncompetitive, and selective *γ-secretase* inhibitor with an IC₅₀ of 6.2 nM. Inhibition of Notch signaling by Nirogacestat dihydrobromide while minimizing gastrointestinal toxicity presents a promising approach for research of Notch receptor-dependent cancers .

HY-159836

Nivegacetor RG6289	γ-secretase	Neurological Disease
Nivegacetor is a potent *γ-secretase* modulator .

HY-13027G

DAPT GSI-IX	γ-secretase	Neurological Disease Inflammation/Immunology Cancer
DAPT (GSI-IX) (GMP) is DAPT (HY-13027) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DAPT is a potent and orally active *γ-secretase* inhibitor .

HY-120789

PF-06648671	γ-secretase	Neurological Disease
PF-06648671 is a novel, brain-penetrable, and orally active γ-secretase modulator (GSM). PF-06648671 reduces Aβ42 and Aβ40, with concomitant increases in Aβ37 and Aβ38 in vitro. PF-06648671 is used for the study of Alzheimer’s disease .

HY-B1786

Sulindac sulfide 1 Publications Verification cis-Sulindac sulfide	Drug Metabolite γ-secretase	Neurological Disease
Sulindac sulfide is a noncompetitive *γ-secretase* inhibitor, with an IC₅₀ of 20.2 μM for γ₄₂-secretase activity.

HY-50883

BMS 299897	γ-secretase	Neurological Disease
BMS 299897 is a sulfonamide *γ-secretase* inhibitor with an IC₅₀ of 7 nM for Aβ production inhibition in HEK293 cells stably overexpressing amyloid precursor protein (APP).

HY-15670

BMS-906024 3 Publications Verification	γ-secretase Notch	Cancer
BMS-906024 is an orally active and selective **γ-secretase (gamma secretase) inhibitor. BMS-906024 is a potent pan-Notch receptors inhibitor with IC₅₀**s of 1.6 nM, 0.7 nM, 3.4 nM, and 2.9 nM for Notch1, -2, -3, and -4 receptors, respectively. BMS-906024 demonstrates broad-spectrum antineoplastic activity .

HY-14174

MRK-560 4 Publications Verification	γ-secretase	Neurological Disease Cancer
MRK-560, a chemical probe, is an orally active, brain barrier-penetrated *γ-Secretase* inhibitor, reducing Aβ peptide in rat brain and cerebrospinal fluid. MRK-560 decreases mutant NOTCH1 processing by selectively inhibiting PSEN1. MRK-560 can be used in studies of Alzheimer's disease and T-cell acute lymphoblastic leukaemia (T-ALL) .

HY-100604

JNJ-40418677	γ-secretase Amyloid-β	Neurological Disease
JNJ-40418677 is an orally active modulator of *γ-secretase, can cross the blood-brain barrier. JNJ-40418677 inhibits Aβ42* and NS2B-NS3 protease, with IC₅₀s of 200 nM and 3.9 μM, respectively. JNJ-40418677 displays good biological tolerance, can be use for Alzheimer’s disease research .

HY-76562

Methyl 6-bromopicolinate	Biochemical Assay Reagents	Others
Methyl 6-bromopicolinate is a synthetic intermediate used in the preparation of *γ-secretase* inhibitor library scaffolds .

HY-N2319

Dihydroergocristine mesylate 1 Publications Verification DHEC mesylate	Amyloid-β	Neurological Disease
Dihydroergocristine mesylate (DHEC mesylate) is a inhibitor of γ-secretase (GSI), reduces the production of the Alzheimer's disease amyloid-β peptides, binds directly to γ-secretase and Nicastrin with equilibrium dissociation constants (K_d) of 25.7 nM and 9.8 μM, respectively .

HY-10043

gamma-secretase modulator 1	γ-secretase	Neurological Disease
γ-secretase inhibitior-1 is a gamma-secretase modulator, γ-secretase inhibitior-1 is useful for Alzheimer's disease.

HY-18614

LY900009	Notch γ-secretase	Cancer
LY900009 is a potent and orally active, First-in-class inhibitor of Notch signaling via selective inhibition of the γ-secretase protein (GSI). LY900009 inhibits Notch signalling in tumor cell lines and endothelial cells (IC₅₀=0.005-20 nM). LY900009 can be used for advanced cancer research .

HY-150049

γ-Secretase modulator 13	Amyloid-β	Neurological Disease
γ-Secretase modulator 13 (compound 4) is a gamma-secretase modulator (GSMs) that inhibits the production of the aggregated amyloid β-peptide Aβ42 with an IC₅₀ value of 163 nM. γ-Secretase modulator 13 can be used in the study of Alzheimer's disease .

HY-108714

NGP555	γ-secretase	Neurological Disease
NGP555 is a *γ-secretase* modulator. NGP555 Lowers the Amyloid Biomarker Aβ42 .

HY-111360

SPL-707 1 Publications Verification	γ-secretase	Inflammation/Immunology
SPL-707 is an orally active, selective signal peptide peptidase-like 2a (SPPL2a) inhibitor with an IC₅₀ of 77 nM for hSPPL2a. SPL-707 inhibits *γ-secretase* (IC₅₀=6.1 μM) and SPP (IC₅₀=3.7 μM). SPL-707 has the potential for autoimmune diseases research by targeting B cells and dendritic cells .

HY-119165

GSM-1	γ-secretase	Neurological Disease
GSM-1 is a potent *γ-secretase* modulator. GSM-1 directly targets the transmembrane domain (TMD) 1 of presenilin 1 (PS1) .

HY-117482

BPN-15606	γ-secretase	Neurological Disease
BPN-15606 is a highly potent, orally active *γ-secretase* modulator (GSM), attenuates the production of Aβ42 and Aβ40 by SHSY5Y neuroblastoma cells with IC₅₀ values of 7 nM and 17nM, respectively. BPN-15606 lowers Aβ42 and Aβ40 levels in the central nervous system of rats and mice. BPN-15606 has acceptable PK/PD properties, including bioavailability, half-life, and clearance .

HY-171347

gamma-secretase modulator 6	γ-secretase Amyloid-β	Neurological Disease
gamma-secretase modulator 6 (Example 50) is a *gamma-secretase* modulator. gamma-secretase modulator 6 inhibits Aβ42 secretion in HEK cell line stably expressing APP (Aβ amyloid precursor protein) (pIC₅₀: 8.1). gamma-secretase modulator 6 can be used for research of Alzheimer's disease .

HY-16632

ELND 006	γ-secretase Amyloid-β	Metabolic Disease
ELND 006 (Compound 30) is a metabolically stable γ-secretase inhibitor designed to selectively inhibit amyloid beta (Aβ) generation while sparing Notch signaling. It was developed through a synthetic strategy emphasizing diversity and chirality. ELND 006, along with its analog ELND007 (Compound 34), progressed into human clinical trials. In preclinical studies, both compounds demonstrated effective reduction of Aβ levels in vitro and in vivo. Comparisons with other γ-secretase inhibitors like Semagacestat, Begacestat, and Avagacestat underscored their potency and specificity in lowering Aβ levels in cerebrospinal fluid (CSF) of healthy human volunteers, suggesting potential therapeutic efficacy in Alzheimer's disease .

HY-B1786A

(E/Z)-Sulindac sulfide	γ-secretase Amyloid-β	Neurological Disease
(E/Z)-Sulindac sulfide is a potent *γ-secretase* modulator (GSM). (E/Z)-Sulindac sulfide selectively reduces Aβ42 production in favor of shorter Aβ species. (E/Z)-Sulindac sulfide can be used for researching Alzheimer’s disease .

HY-120234

Z-LLNle-CHO Z-Leu-Leu-Nle-CHO; GSII	γ-secretase Proteasome Apoptosis	Cancer
Z-LLNle-CHO (Z-Leu-Leu-Nle-CHO) is a *γ-secretase* inhibitor I. Z-LLNle-CHO induces caspase and ROS-dependent apoptosis by blocking the Akt-mediated pro-survival pathway. Z-LLNle-CHO can be used in cancer research, such as breast cancer and leukaemia .

HY-145343

RO7185876	γ-secretase	Neurological Disease
RO7185876 is a potent and selective *gamma secretase* modulator as a potential research for Alzheimer's disease.

HY-171444

GSM III	γ-secretase Amyloid-β	Neurological Disease
GSM III is a γ-Secretase complexe (GSEC) modulator. GSM III significantly regulates amyloid-β (Aβ) length at the extracellular interface between the protease (NCT, PSEN) and the substrate APP_C99. GSM III can be used for Alzheimer's disease (AD) research .

HY-171348

Amyloid-β-IN-2	Amyloid-β γ-secretase	Neurological Disease
Amyloid-β-IN-2 (Compound EX.112) is a selective *γ-secretase* inhibitor. Amyloid-β-IN-2 inhibits Aβ42 secretion in H4 cells with an EC₅₀ value of 226 nM. Amyloid-β-IN-2 is promising for research of Alzheimer's disease (AD) and other diseases related to Aβ deposition .

HY-50882

ELN318463	γ-secretase	Neurological Disease
ELN318463 is an amyloid precursor protein (APP) selective *γ-secretase* inhibitor. ELN318463 shows differential inhibition of presenilin (PS1)- and PS2-comprised γ-secretase with EC₅₀s of 12 nM and 656 nM for PS1 and PS2, respectively. ELN318463 is 51-fold more selective for PS1 .

HY-15211

MRK 003	γ-secretase Apoptosis	Neurological Disease Cancer
MRK 003 is a potent, selective and orally active *γ-secretase* inhibitor. MRK 003 reduce brain Aβ production in vivo. MRK 003 induces caspase-dependent apoptosis and inhibits tumor cell proliferation in vivo and in vitro .

HY-148306

γ-Secretase modulator 14	γ-secretase	Neurological Disease
γ-Secretase modulator 14 is a *γ-secretase* modulator. γ-Secretase modulator 14 has the potenial for Alzheimer's disease (AD) research (WO2013010904A1; compound 42) .

HY-14176G

Compound E γ-Secretase-IN-1	γ-secretase	Cancer
Compound E (GMP) is a GMP-grade Compound E (HY-14176). GMP-grade small molecules can be used as adjuvant reagents in cell therapy. Compound E is a *γ-secretase* inhibitor. Compound E inhibits β-amyloid(40), β-amyloid(42), and Notch γ-secretase cleavage with IC₅₀ values of 0.24, 0.37, and 0.32 nM, respectively .

HY-146151

γ-Secretase modulator 12	γ-secretase Amyloid-β	Neurological Disease
γ-Secretase modulator 12 (Compound 1a) is a *γ-secretase* modulator that can selectively decrease amyloid-β42 (Aβ42) levels (IC₅₀ of 0.39 µM). γ-Secretase modulator 12 can be used for Alzheimer’s disease research. γ-Secretase modulator 12 has a good brain/plasma ratio (Kp, brain = 0.72) in mice .

HY-50900

gamma-Secretase Modulators Amyloid-β production inhibitor; γ-Secretase Modulators	Amyloid-β	Neurological Disease
gamma-Secretase Modulators (Amyloid-β production inhibitor) is a Amyloid-β production inhibitor.

HY-171349

Amyloid-β-IN-3	γ-secretase Amyloid-β	Neurological Disease
Amyloid-β-IN-3 (EX.113) is a selective *γ-secretase* inhibitor. Amyloid-β-IN-3 inhibits Aβ42 secretion in H4 cells with an EC₅₀ value of 148 nM. Amyloid-β-IN-3 regulates the γ-secretase catalytic activity to decrease Aβ42 production, thereby alleviating neurotoxicity caused by Aβ deposition. Amyloid-β-IN-3 is promising for research of Alzheimer's disease (AD) .

HY-145372

γ-Secretase modulator 10	γ-secretase	Neurological Disease
γ-Secretase modulator 10 is a novel *γ-secretase* modulator.

HY-147720A

γ-Secretase modulator 11 hydrochloride	γ-secretase	Neurological Disease
γ-Secretase modulator 11 hydrochloride (compound 1o) is a potent and orally active *γ-secretase* modulator with an IC₅₀ of 0.029 µM. γ-Secretase modulator 11 hydrochloride induces a robust reduction in brain Aβ42 levels. γ-Secretase modulator 11 hydrochloride rescues cognitive deficits exhibited by AD model mice. γ-Secretase modulator 11 hydrochloride has the potential for the research of alzheimer's disease .

HY-128581

γ-Secretase modulator 4	γ-secretase	Neurological Disease
γ-Secretase modulator 4 is a potent *γ-secretase* modulator, reduces the Aβ42 level with IC₅₀s of 0.014 μM and 0.017 μM in human and mouse, respectively .

HY-14176A

(1R,3S)-Compound E	γ-secretase	Cancer
(1R,3S)-Compound E is the isomer of Compound E (HY-14176), and can be used as an experimental control. Compound E is a *γ-secretase* inhibitor. Compound E bloks β-amyloid(40), β-amyloid(42), and Notch γ-secretase cleavage with IC₅₀s of 0.24, 0.37, 0.32 nM, respectively.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N11709

Theasaponin E1	Triterpenes Structural Classification Terpenoids Camellia sinensis (L.) O. Ktze. Plants Source Classification Theaceae	Apoptosis VEGFR ATM/ATR PTEN Akt mTOR HIF/HIF Prolyl-Hydroxylase NF-κB Notch Cholinesterase (ChE) Amyloid-β γ-secretase Ferroptosis Fungal
Theasaponin E1 is an orally effective tea saponin. Theasaponin E1 inhibits the proliferation of cancer cells by activating apoptosis. Theasaponin E1 inhibits angiogenesis in ovarian cancer cells and HUVECs by reducing the expression of VEGF. Theasaponin E1 upregulates the phosphorylation level of ATM protein and the expression level of PTEN protein in cancer cells, decreases the phosphorylation levels of Akt, mTOR, p70S6K and 4E-BP1 proteins, downregulates the expression of HIF-1α and NF-κB, and reduces the protein expression of Notch ligands Dll4 and Jagged1. Theasaponin E1 exerts neuroprotective effects by inhibiting the activity of acetylcholinesterase, activating *α-secretase* and neprilysin, reducing the concentration of Aβ, and inhibiting the activities of *β-secretase* and *γ-secretase. Theasaponin E1 exhibits toxic effects on cancer cells and quinone reductase-inducing activity, and inhibits tumor growth in vivo. Theasaponin E1 induces ferroptosis* in Pomacea canaliculata by synergistically disrupting cholesterol homeostasis and sphingolipid metabolism. Theasaponin E1 possesses anti-biofilm activity against Candida albicans. Theasaponin E1 can be used in the research of ovarian cancer, obesity, Alzheimer's disease and fungal infections .

HY-N8890

Demissidine	Structural Classification Alkaloids Steroid Alkaloids Solanum tuberosum L. Solanaceae Plants Source Classification	Beta-secretase γ-secretase
Demissidine is an alkaloid that can be isolated from potato . Demissidine is a promising dual inhibitors against β- and γ-secretase proteins in silico .

Cat. No.	Product Name	Chemical Structure

HY-B1786S

Sulindac sulfide-d3
Sulindac sulfide-d₃ is deuterium labeled Sulindac sulfide. Sulindac sulfide is a noncompetitive γ-secretase inhibitor, with an IC50 of 20.2 μM for γ42-secretase activity.

Targets Recommended: γ-secretase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14176G

Compound E γ-Secretase-IN-1	γ-secretase	Cancer
Compound E (GMP) is a GMP-grade Compound E (HY-14176). GMP-grade small molecules can be used as adjuvant reagents in cell therapy. Compound E is a *γ-secretase* inhibitor. Compound E inhibits β-amyloid(40), β-amyloid(42), and Notch γ-secretase cleavage with IC₅₀ values of 0.24, 0.37, and 0.32 nM, respectively .

HY-13027G

DAPT GSI-IX	γ-secretase	Neurological Disease Inflammation/Immunology Cancer
DAPT (GSI-IX) (GMP) is DAPT (HY-13027) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DAPT is a potent and orally active *γ-secretase* inhibitor .

HY-13526G

YO-01027 Dibenzazepine; DBZ	Notch γ-secretase	Cancer
YO-01027 (Dibenzazepine) (GMP) is YO-01027 (HY-13526) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. YO-01027 is a potent *γ-secretase* inhibitor .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

γ-Secretase

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Oligonucleotides

GMP Molecules

Natural
Products